Gilead’s Q4 Revenue $7.93B Tops Estimates, EPS $1.86 Beats
Gilead’s Q4 revenue reached $7.93 billion, up 4.7% year-over-year, surpassing consensus by 4.6%, while EPS of $1.86 beat estimates by 1.9%. U.S. product sales were led by Biktarvy at $3.97 billion (+5.1%), offset by a 37.1% decline in Veklury to $212 million.
1. Q4 Financial Results
Gilead reported fourth-quarter revenue of $7.93 billion, representing a 4.7% increase year-over-year, and EPS of $1.86, marking beats of 4.6% on revenue and 1.9% on earnings versus consensus estimates.
2. Product Segment Performance
U.S. HIV therapy Biktarvy led product sales with $3.97 billion, up 5.1%, while Veklury sales declined 37.1% to $212 million. Liver disease franchise saw a 189.7% jump in other liver disease sales to $168 million, partially offsetting weakness in other segments.
3. Market Response and Positioning
Gilead shares have gained 23.7% over the past month, reflecting investor focus on its core franchises. The stock holds a neutral rating, indicating performance in line with broader market trends in the near term.